Go Deep
Boston Scientific Corporation
Boston Scientific Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,929 | 17.0 | 2.48 | 0.50 | 4,126.36 |
| Oct 2026 | 21,791 | 17.7 | 2.55 | 0.50 | 4,197.26 |
| Oct 2026 | 22,083 | 17.5 | 2.52 | 0.50 | 4,124.57 |
| Oct 2026 | 22,106 | 17.4 | 2.50 | 0.50 | 4,082.74 |
| Oct 2026 | 22,019 | 18.0 | 2.57 | 0.50 | 4,191.58 |
| Oct 2026 | 22,000 | 18.0 | 2.58 | 0.50 | 4,204.40 |
| Oct 2026 | 21,949 | 18.2 | 2.62 | 0.50 | 4,271.48 |
| Oct 2026 | 21,908 | 18.5 | 2.65 | 0.50 | 4,321.73 |
| Oct 2026 | 21,990 | 18.0 | 2.59 | 0.50 | 4,209.85 |
| Oct 2026 | 21,875 | 18.6 | 2.67 | 0.50 | 4,342.92 |
| Oct 2026 | 21,900 | 18.5 | 2.66 | 0.50 | 4,330.60 |
Boston Scientific Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 5,442,000,000.0 | 5,203,000,000.0 | 5,286,000,000.0 | 5,065,000,000.0 |
| Net Profit | 907,000,000.0 | 1,341,000,000.0 | 672,000,000.0 | 755,000,000.0 |
| EPS | 0.6 | 0.9 | 0.5 | 0.5 |
Boston Scientific Corporation Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 20,074,000,000.0 | 16,747,000,000.0 | 14,240,000,000.0 | 12,682,000,000.0 | — |
| Net Profit | 2,898,000,000.0 | 1,854,000,000.0 | 1,593,000,000.0 | 698,000,000.0 | — |
| EPS | 2.0 | 1.3 | 1.1 | 0.5 | — |
Boston Scientific Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 43,673,000,000.0 | 39,395,000,000.0 | 35,136,000,000.0 | 32,469,000,000.0 | — |
| Total Liabilities | 19,201,000,000.0 | 17,392,000,000.0 | 15,606,000,000.0 | 14,896,000,000.0 | — |
| Total Equity | 24,232,000,000.0 | 21,770,000,000.0 | 19,281,000,000.0 | 17,574,000,000.0 | — |
Owes vs Owns
Boston Scientific Corporation owed $0.44 for every $1 it owned in Jun 2026, down from $0.46 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.44× | 0.44× | 0.44× | 0.44× | 0.46× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Boston Scientific Corporation Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 4.5%Receivables 6.7%Inventory 6.7%Fixed assets (tangible) 9.2%Intangible assets 57.9%Other assets 14.9%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 25.2%Payables 2.6%Other liabilities 15.4%Shareholders' equity 56.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,965.0 | 414.0 | 865.0 | 928.0 |
| Receivables | 2,926.0 | 2,558.0 | 2,228.0 | 1,970.0 |
| Inventory | 2,943.0 | 2,810.0 | 2,484.0 | 1,867.0 |
| Fixed assets (tangible) | 4,035.0 | 3,295.0 | 3,298.0 | 2,831.0 |
| Intangible assets | 25,302.0 | 23,773.0 | 20,390.0 | 18,823.0 |
| Long-term investments | 0.0 | 555.0 | 413.0 | 407.0 |
| Other assets | 6,502.0 | 5,990.0 | 5,458.0 | 5,643.0 |
| Liabilities & equity | ||||
| Short-term debt | 299.0 | 1,778.0 | 531.0 | 20.0 |
| Long-term debt | 11,012.0 | 8,842.0 | 8,566.0 | 8,910.0 |
| Payables | 1,144.0 | 960.0 | 942.0 | 862.0 |
| Other liabilities | 6,746.0 | 5,812.0 | 5,567.0 | 5,104.0 |
| Shareholders' equity | 24,472.0 | 22,003.0 | 19,530.0 | 17,573.0 |
| Net tangible assets | -1,070.0 | -2,003.0 | -1,109.0 | -1,249.0 |
Boston Scientific Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 4,534,000,000.0 | 3,435,000,000.0 | 2,503,000,000.0 | 1,526,000,000.0 | — |
| Investing Activities | -2,640,000,000.0 | -5,687,000,000.0 | -2,574,000,000.0 | -2,011,000,000.0 | — |
| Financing Activities | -395,000,000.0 | 1,814,000,000.0 | 5,000,000.0 | -548,000,000.0 | — |